Navigation Links
Cleveland Clinic selected to participate in National MDS Clinical Research Consortium
Date:6/7/2012

Thursday, June 7, 2012, Cleveland: Taussig Cancer Institute at Cleveland Clinic will participate in an unprecedented, six-institution consortium designed to conduct clinical trials and research to improve outcomes for patients with myelodysplastic syndrome (MDS). Known as the MDS Clinical Research Consortium, the five-year, $16 million initiative is sponsored by the Aplastic Anemia & MDS International Foundation and supported by the Edward P. Evans Foundation.

This is the first privately funded MDS research consortium in the U.S. Mikkael Sekeres, M.D., M.S., Director of Taussig Cancer Institute's Leukemia Program, will co-chair the Consortium with Guillermo Garcia-Manero, M.D. of MD Anderson Cancer Center. The Consortium will fill a major gap in MDS-related clinical research by providing a new "critical mass" of dedicated institutions to support the evaluation of promising new therapies, epidemiological studies, and translational studies leading to new treatments and classifications for these diseases. It will also sponsor a yearly, dedicated MDS fellowship slot at each institution.

Centralized clinical operations (data collection and management, biostatistics, clinical trial accrual and supervision of research protocols) will be housed at Taussig Cancer Institute. The Consortium will be administered by the Aplastic Anemia & MDS International Foundation.

"This Consortium is the first clinical research network created to support the infrastructure that makes MDS clinical research happen by enabling the collaboration of the leading MDS centers is the U.S.," said Dr. Sekeres.

The other five participating institutions include Dana Farber Cancer Institute; MD Anderson Cancer Center; H. Lee Moffitt Cancer Center and Research Institute; Weill Medical College of Cornell University; and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

"One of the greatest challenges in research of rare diseases like MDS is having enough patients to conduct meaningful clinical trials. No single center can do it alone. This uniquely collaborative effort overcomes that barrier," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. "To have these six leading MDS research centers working together in this way is unprecedented."

Programs selected as part of the Consortium are based at U.S. academic medical centers that serve a high volume of MDS patients; that maintain a current and historical patient data base; and that have a current and retrospective MDS patient cohort of sufficient size to have a very significant track record of participation in MDS-related clinical trials.

MDS is a cancer of hematopoietic bone marrow stem cells akin to leukemia that inhibits the body's ability to produce healthy blood cells. It principally affects adults over the age of 60 years, and can be treated with chemotherapy, growth factor, or immuonomodulatory therapies. At present, the only cure is a bone marrow transplant.


'/>"/>
Contact: Joe Milicia
milicij2@ccf.org
216-312-0591
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic, youth mental health experts, publish new guidelines to treat childhood aggression
2. Mayo Clinic Alzheimers researcher honored twice in a month
3. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
4. Canada should significantly increase its funding of randomized clinical trials
5. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
6. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
7. Experts call for clinical trials to test non-skeletal benefits of vitamin D
8. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
9. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: